Information Provided By: 
Fly News Breaks for March 12, 2019
ZGNX
Mar 12, 2019 | 06:00 EDT
Mizuho analyst Difei Yang says Zogenix remains one of her top picks in 2019. Fintepla's "unique" mechanism of action has been a key part of the "impressive" data observed in Dravet syndrome, a relatively homogeneous disease, Yang tells investors in a research note. She believes data in new indications "will be an important part of the story" and reiterates a Buy rating on Zogenix with a $69 price target.
News For ZGNX From the Last 2 Days
There are no results for your query ZGNX
